Theratechnologies Receives FDA Approval For EGRIFTA WR™ (Tesamorelin F8) To Treat Excess Visceral Abdominal Fat In Adults With HIV And Lipodystrophy
New, improved formulation set to replace EGRIFTA SV® MONTREAL, March 25, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Thera ...
Le Lézard8h
Theratechnologies Receives FDA Approval for EGRIFTA WRtm (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy
Theratechnologies Inc. ("Theratechnologies" or the "Company") , a commercial-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved the ...